Universal BCMA-CD19 CAR-T

Universal BCMA-CD19 CAR-T is a cell therapy that utilizes genetically engineered T-cells to express chimeric antigen receptors (CARs) targeting both B-cell maturation antigen (BCMA) and Cluster of Differentiation 19 (CD19). This dual-targeting approach aims to enhance efficacy and prevent antigen escape in diseases where these markers are expressed. BCMA is a protein found on plasma cells and is often overexpressed in multiple myeloma, while CD19 is a protein found on B cells and is a common target in B-cell malignancies and autoimmune diseases. The therapy is being developed by Bioray Laboratories for indications such as refractory AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disease (NMOSD) and refractory Lupus Nephritis.

Other names

BRL-302BRL302BRL 302PSMA-UCAR T